These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 34503244)

  • 21. The hepatitis B virus X protein promotes pancreatic cancer through modulation of the PI3K/AKT signaling pathway.
    Chen Y; Bai X; Zhang Q; Wen L; Su W; Fu Q; Sun X; Lou Y; Yang J; Zhang J; Chen Q; Wang J; Liang T
    Cancer Lett; 2016 Sep; 380(1):98-105. PubMed ID: 27339327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT signaling pathway in pancreatic ductal adenocarcinoma.
    Zhang Y; Zhang R; Luo G; Ai K
    J Cancer; 2018; 9(15):2713-2722. PubMed ID: 30087712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
    Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
    Front Oncol; 2020; 10():621937. PubMed ID: 33520728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global targetome analysis reveals critical role of miR-29a in pancreatic stellate cell mediated regulation of PDAC tumor microenvironment.
    Dey S; Liu S; Factora TD; Taleb S; Riverahernandez P; Udari L; Zhong X; Wan J; Kota J
    BMC Cancer; 2020 Jul; 20(1):651. PubMed ID: 32660466
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment.
    Javadrashid D; Baghbanzadeh A; Derakhshani A; Leone P; Silvestris N; Racanelli V; Solimando AG; Baradaran B
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33918146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting phosphoinositide 3-kinase pathways in pancreatic cancer--from molecular signalling to clinical trials.
    Falasca M; Selvaggi F; Buus R; Sulpizio S; Edling CE
    Anticancer Agents Med Chem; 2011 Jun; 11(5):455-63. PubMed ID: 21521159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting.
    Cheung PF; Neff F; Neander C; Bazarna A; Savvatakis K; Liffers ST; Althoff K; Lee CL; Moding EJ; Kirsch DG; Saur D; Bazhin AV; Trajkovic-Arsic M; Heikenwalder MF; Siveke JT
    Cancer Res; 2018 Sep; 78(17):4997-5010. PubMed ID: 29844119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting.
    Jonckheere N; Vasseur R; Van Seuningen I
    Crit Rev Oncol Hematol; 2017 Mar; 111():7-19. PubMed ID: 28259298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
    Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling.
    Kong B; Wu W; Cheng T; Schlitter AM; Qian C; Bruns P; Jian Z; Jäger C; Regel I; Raulefs S; Behler N; Irmler M; Beckers J; Friess H; Erkan M; Siveke JT; Tannapfel A; Hahn SA; Theis FJ; Esposito I; Kleeff J; Michalski CW
    Gut; 2016 Apr; 65(4):647-57. PubMed ID: 25601637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.
    Polo ML; Riggio M; May M; Rodríguez MJ; Perrone MC; Stallings-Mann M; Kaen D; Frost M; Goetz M; Boughey J; Lanari C; Radisky D; Novaro V
    Oncotarget; 2015 Sep; 6(26):22081-97. PubMed ID: 26098779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A blockade of PD-L1 produced antitumor and antimetastatic effects in an orthotopic mouse pancreatic cancer model via the PI3K/Akt/mTOR signaling pathway.
    Zhao L; Li C; Liu F; Zhao Y; Liu J; Hua Y; Liu J; Huang J; Ge C
    Onco Targets Ther; 2017; 10():2115-2126. PubMed ID: 28442920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches.
    Truong LH; Pauklin S
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway.
    Zhang H; Pan YZ; Cheung M; Cao M; Yu C; Chen L; Zhan L; He ZW; Sun CY
    Cell Death Dis; 2019 Mar; 10(3):230. PubMed ID: 30850586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications.
    Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S
    Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer.
    Ning C; Liang M; Liu S; Wang G; Edwards H; Xia Y; Polin L; Dyson G; Taub JW; Mohammad RM; Azmi AS; Zhao L; Ge Y
    Oncotarget; 2017 Jul; 8(27):44295-44311. PubMed ID: 28574828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.